Cite
Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models
MLA
Tatsuo Sugawara, et al. “Abstract 651: Combination of the Androgen Receptor Inhibitor Darolutamide and the PI3K Inhibitor Copanlisib Leads to Improved Anti-Tumor Efficacy and Apoptosis in Prostate Cancer Models.” Cancer Research, vol. 82, June 2022, p. 651. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........16aba4f051df93eff69cbff300d5acdd&authtype=sso&custid=ns315887.
APA
Tatsuo Sugawara, Holly NGuyen, Eva Corey, Ekaterina Nevedomskaya, Oliver Politz, Dominik Mumberg, & Bernard Haendler. (2022). Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models. Cancer Research, 82, 651.
Chicago
Tatsuo Sugawara, Holly NGuyen, Eva Corey, Ekaterina Nevedomskaya, Oliver Politz, Dominik Mumberg, and Bernard Haendler. 2022. “Abstract 651: Combination of the Androgen Receptor Inhibitor Darolutamide and the PI3K Inhibitor Copanlisib Leads to Improved Anti-Tumor Efficacy and Apoptosis in Prostate Cancer Models.” Cancer Research 82 (June): 651. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........16aba4f051df93eff69cbff300d5acdd&authtype=sso&custid=ns315887.